207_Combined course Presentations

DAHANCA19: Secondary endpoints

Disease specific Overall survival

control 80%

control 69%

zalutumumab 78%

zalutumumab 63%

HR: 1.04 [95% CI: 0.72-1.52]

HR: 1.16 [95% CI: 0.87-1.55]

Pts. at risk Events

Pts. at risk Events

zalutumumab 301

56 53

zalutumumab 301

99 84

control

307 608

control

307 608

total

109

total

183

Eriksen, ICHNO 2015